Industry
Biotechnology
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:51 pm
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 7:37 pm
Portfolio Pulse from Vandana Singh
August 01, 2024 | 5:42 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:34 am
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 1:32 pm
Portfolio Pulse from Benzinga Newsdesk
June 15, 2024 | 4:38 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 12:40 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.